Patient characteristics
| Characteristic . | Total . |
|---|---|
| Number of patients | 137 |
| Male sex | 82 (60) |
| Age at transplant (y), median (range) | 7.4 (0.2-22.7) |
| Patients receiving ATG | 112 (82) |
| Diagnosis | |
| Malignancy | 56 (41) |
| ALL | 22 (16) |
| AML | 30 (22) |
| Lymphoma | 4 (3) |
| PID | 33 (24) |
| BM failure | 7 (5) |
| Benign non-PID | 41 (30) |
| Conditioning regimen | |
| Bu-Flu | 92 (67) |
| Bu-Flu-Clo | 30 (22) |
| TBI based | 10 (7) |
| Cy-Flu | 5 (4) |
| Match grade | |
| 6/6 matched | 55 (40) |
| 5/6 matched | 63 (46) |
| 4/6 matched | 18 (13) |
| 3/6 matched | 1 (1) |
| Follow-up (mo), median (range) | 44 (0.2-143) |
| Characteristic . | Total . |
|---|---|
| Number of patients | 137 |
| Male sex | 82 (60) |
| Age at transplant (y), median (range) | 7.4 (0.2-22.7) |
| Patients receiving ATG | 112 (82) |
| Diagnosis | |
| Malignancy | 56 (41) |
| ALL | 22 (16) |
| AML | 30 (22) |
| Lymphoma | 4 (3) |
| PID | 33 (24) |
| BM failure | 7 (5) |
| Benign non-PID | 41 (30) |
| Conditioning regimen | |
| Bu-Flu | 92 (67) |
| Bu-Flu-Clo | 30 (22) |
| TBI based | 10 (7) |
| Cy-Flu | 5 (4) |
| Match grade | |
| 6/6 matched | 55 (40) |
| 5/6 matched | 63 (46) |
| 4/6 matched | 18 (13) |
| 3/6 matched | 1 (1) |
| Follow-up (mo), median (range) | 44 (0.2-143) |
Values are n (%) of patients unless indicated otherwise.
Bu, busulfan; Clo, clofarabine; Flu, fludarabine; PID, primary immune deficiency; TBI, total body irradiation.